Core Insights - Illumina reported $1.08 billion in revenue for Q3 2025, a year-over-year increase of 0.4%, with an EPS of $1.34 compared to $1.14 a year ago, exceeding both revenue and EPS estimates [1][2] Revenue Breakdown - Product revenue reached $927 million, surpassing the estimated $899.38 million, reflecting a year-over-year increase of 1.4% [4] - Service and other revenue was $157 million, below the average estimate of $165.17 million, indicating a year-over-year decline of 5.4% [4] - Consumable product revenue was $816 million, slightly above the estimated $803.8 million, marking a year-over-year increase of 1.1% [4] - Instrument product revenue was $111 million, exceeding the estimate of $105.1 million, with a year-over-year increase of 3.7% [4] - Sequencing consumables revenue was $747 million, above the estimate of $737.64 million, showing a year-over-year increase of 0.8% [4] - Sequencing instruments revenue was $107 million, slightly above the estimate of $106.24 million, with a year-over-year increase of 2.9% [4] - Microarrays consumables revenue was $69 million, close to the estimate of $69.75 million, reflecting a year-over-year increase of 4.6% [4] - Microarrays instruments revenue was $4 million, exceeding the estimate of $3.35 million, indicating a significant year-over-year increase of 33.3% [4] Stock Performance - Illumina's shares have returned -7.1% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change, and the stock currently holds a Zacks Rank 3 (Hold) [3]

Core Insights - Illumina reported revenue of $1.04 billion for the quarter ended March 2025, reflecting a 3.3% decrease year-over-year, while EPS increased to $0.97 from $0.09 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate by 0.25%, and the EPS also surpassed the consensus estimate by 1.04% [1] Revenue Breakdown - Product revenue was $880 million, slightly above the average estimate of $872.04 million, marking a year-over-year increase of 0.5% [4] - Core Illumina service and other revenue totaled $161 million, below the average estimate of $175.08 million, representing a year-over-year decline of 6.9% [4] - Total product revenue for Core Illumina was $880 million, compared to the average estimate of $869.69 million, showing a year-over-year decrease of 0.3% [4] - Service and other revenue was $161 million, below the average estimate of $170.12 million, with a significant year-over-year decline of 19.5% [4] - Sequencing instruments revenue reached $109 million, slightly above the estimated $108.51 million, reflecting a year-over-year decrease of 0.9% [4] - Core Illumina instruments revenue was $112 million, in line with the average estimate of $112.06 million, showing a year-over-year decline of 1.8% [4] - Sequencing consumables revenue was $696 million, exceeding the estimated $679.85 million, with a year-over-year decrease of 0.3% [4] - Microarrays instruments revenue was $3 million, below the estimated $3.61 million, representing a significant year-over-year decline of 25% [4] - Microarrays consumables revenue was $72 million, slightly below the average estimate of $74.59 million, with a year-over-year increase of 1.4% [4] - Overall, Core Illumina revenue was $1.04 billion, surpassing the average estimate of $1.03 billion, but reflecting a year-over-year decline of 1.4% [4] - Core Illumina consumables revenue was $768 million, exceeding the estimated $748.87 million, with a year-over-year decrease of 0.1% [4] Stock Performance - Illumina's shares returned 0.1% over the past month, compared to a 11.3% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]